Biotrial
Private Company
Total funding raised: $56M
Overview
Biotrial is a well-established, France-based CRO with over 35 years of experience in drug development services. It provides an integrated suite of offerings spanning preclinical pharmacology (efficacy, safety, PK), clinical development (notably Phase I studies in healthy volunteers and special populations), and specialized support services like biometrics, bioanalysis, and data science. The company operates globally with Clinical Pharmacology Units in the US and France, positioning it as a partner for biotech and pharma companies seeking to de-risk and accelerate their R&D programs.
Technology Platform
Integrated CRO service platform encompassing Preclinical Pharmacology (in vitro/in vivo efficacy, safety, PK), Clinical Development with owned Phase I units, and specialized support labs (Bioanalysis, Biometrics, ECG, CNS & Imaging Core Lab). Enhanced by Data Science/AI capabilities via acquisition of ExactCure.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| EXS21546 | Advanced Solid Tumours | Phase 1/2 | |
| Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY5... | Duchenne Muscular Dystrophy | Phase 1/2 | |
| LPH-5 + Placebo | Safety Issues | Phase 1 | |
| Binimetinib Oral Tablet | Melanoma | Phase 1 | |
| ITF2357 | Hepatic Impairment | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive global CRO market, competing against large public players (e.g., IQVIA, LabCorp, Parexel) and many specialized mid-sized and boutique CROs. Differentiates through integrated early-phase services, owned clinical pharmacology units, and specialized core labs (e.g., CNS & Imaging).